InMode Ltd. ( INMD ) was founded in 2008 and is based in Israel. It is a global leader in non-/minimally invasive aesthetic medical products, which are based on their proprietary radiofrequency (RF) assisted lipolysis and deep subdermalI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believ ...

InMode Ltd. ( INMD ) was founded in 2008 and is based in Israel. It is a global leader in non-/minimally invasive aesthetic medical products, which are based on their proprietary radiofrequency (RF) assisted lipolysis and deep subdermalI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believ ...

Summary of InMode Conference Call Company Overview - **Company**: InMode - **Founded**: 17 years ago by Moshe Mizrahy - **Headquarters**: Israel - **Employees**: 650 worldwide, plus 200 in manufacturing - **Revenue Growth**: From $22 million in 2017 to $500 million in 2023, indicating rapid growth [7][20] Core Business and Technology - **Focus**: Aesthetic and wellness medical treatments, utilizing minimally invasive technology rather than traditional optical energy methods [6][8] - **Key Products**: - BodyTite platforms for fat melting and skin tightening - Empower for women's health, targeting vaginal laxity and urinary incontinence - InVision for dry eye treatment [7][12][13] Market Dynamics - **Current Market Challenges**: - Revenue decline of 20% expected in 2024 due to high inflation (8%-9%) and increased interest rates (13%-14%) affecting equipment financing for doctors [19][20] - Projected revenue for 2023 is approximately $370 million [20][21] - **Gross Margin**: Maintained at 80% despite market challenges, with EBITDA above 20% [20] Future Growth Opportunities - **Women's Health**: - Ongoing FDA studies for urinary incontinence and overactive bladder, expected to complete by end of 2026 [11][14] - Empower product generated $40 million in its first year [12] - **Ophthalmology**: - InVision product for dry eye treatment sold $30 million in its first year, with expectations to exceed $50 million annually in the future [13] - **International Expansion**: - Established subsidiaries in Japan, Argentina, and Thailand, aiming to increase direct sales from 80% to 85% [22][24] - Potential growth in China, with plans to expand product offerings as additional clearances are obtained [24][38] Sales and Marketing Strategy - **Sales Force**: - Approximately 300 direct salespeople globally, with 210 in the U.S. [30] - Leadership changes made to streamline management and improve sales momentum [31][32] - **Marketing Investments**: Increased spending on marketing to support direct sales efforts [22] Financial Strategy - **Capital Allocation**: - $508 million spent on stock buybacks, with a shift in focus towards exploring M&A opportunities [33][34] - No current M&A pipeline, but interest in acquiring companies related to women's health and wellness [34] Product Development - **Upcoming Products**: - Development of four laser types (CO2, Erbium, Q-Switch, PICO) to complement existing RF technology, expected to launch between 2026 and 2027 [35][36] Conclusion - InMode is navigating a challenging market environment but remains optimistic about future growth through product innovation, international expansion, and strategic management of its sales force and financial resources [20][21][22]

Core Insights - InMode Ltd. reported strong financial performance for Q3 2025, with an EPS of $0.38, surpassing the estimated EPS of $0.35 [1][6] - The company's revenue reached approximately $93.2 million, exceeding the estimated revenue of about $90.9 million [2][6] - InMode maintained a robust gross margin of 78%, indicating efficiency in managing production costs [2][6] Financial Metrics - The company has a price-to-earnings (P/E) ratio of approximately 5.1, reflecting the market's valuation of its earnings [4] - The price-to-sales ratio stands at about 2.52, and the enterprise value to sales ratio is around 2, suggesting favorable market value relative to sales [4] - InMode's low debt-to-equity ratio of approximately 0.01 indicates minimal reliance on debt financing [5] - The company boasts a strong current ratio of about 9.6, highlighting its ability to cover short-term liabilities with short-term assets [5] - The earnings yield of about 19.6% provides a measure of return on investment for shareholders [5] Leadership Changes - Michael Dennison has been appointed as the new President of North America, expected to enhance regional strategy and customer engagement [3]

Financial Data and Key Metrics Changes - InMode generated revenues of $93.2 million in Q3 2025, down from $130.2 million in Q3 2024, which included $31.9 million in pre-order sales [6][7] - Consumables and service revenues were $19.9 million, up 26% year-over-year, driven primarily by markets outside the U.S. [6][7] - GAAP gross margins were 78%, down from 82% in Q3 2024, attributed to the impact of tariffs [7][8] - GAAP net income was $21.8 million, down from $50.9 million in Q3 2024, with diluted earnings per share at $0.34, down from $0.65 [9][10] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 75% of total revenues this quarter [7] - Sales outside the U.S. increased slightly to $40 million, or 43% of overall sales, a 10% increase year-over-year [7] - Sales and marketing expenses decreased to $44.9 million from $51.9 million in the same period last year [8] Market Data and Key Metrics Changes - The U.S. was the largest geographical revenue contributor, reaching $53.2 million [7] - The company currently has 284 direct sales reps and distributors covering more than 73 countries [8] Company Strategy and Development Direction - The company is focused on expanding its presence in high-growth markets, recently opening a new subsidiary in Argentina [3][4] - A new leadership addition, Michael Denison, was appointed as President of North America to streamline operations [5][28] - The company aims to launch new products in the aesthetic segment in early 2026, including new lasers [26] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the marketplace but expressed confidence in the company's competitive advantages and strong financial position [5] - The company plans to remain conservative in its guidance for 2026 due to uncertainties in the market [14][16] Other Important Information - The company expects to begin generating initial revenue from its new subsidiary in Argentina by the end of 2025 [4] - Non-GAAP gross margins are expected to remain between 78%-80% for 2025 [10] Q&A Session Summary Question: Guidance for Q4 and 2026 sales growth - Management indicated it is too early to discuss guidance for 2026 and prefers to see how Q4 plays out first [14] Question: Capital equipment environment and interest rates - Management noted that while interest rates have come down, it has not yet significantly impacted capital equipment financing [16][17] Question: Updates on ophthalmology initiative - The company is separating sales teams for the Envision initiative and has made progress with the American Optometrist Association [20][21] Question: New product pipeline in aesthetics - New lasers complementary to the aesthetic portfolio are expected to be launched in early 2026 [26] Question: Rationale for appointing Michael Denison - Denison was chosen for his extensive experience and knowledge of the market, aiming to unify North American operations under one management [28][29] Question: Urology business expectations - The company is launching urology products and will assess their performance by the end of the year [30] Question: Strength in OUS business and future trends - The company is currently selling in 88 to 90 countries and does not plan to add more countries in 2025 [33][34] Question: Non-invasive growth and consumables - The company sold about 230,000 disposable handpieces in Q3 2025, indicating a sequential increase [41]

SAFE HARBOR DISCLAIMER INMODE PROFILE & STRATEGY NOVEMBER 2025 • This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," " ...

Core Insights - InMode Ltd. reported consolidated financial results for Q3 2025, showing a decline in revenues and net income compared to Q3 2024, attributed to cautious consumer sentiment and broader economic challenges [1][4]. Financial Performance - Total revenues for Q3 2025 were $93.2 million, down from $130.2 million in Q3 2024, which included $31.9 million from pre-order sales [3][6]. - Gross margins for Q3 2025 were 78%, compared to 82% in Q3 2024 [7]. - Net income for Q3 2025 was $21.9 million, or $0.34 per diluted share, a decrease from $51.0 million, or $0.65 per diluted share, in Q3 2024 [9]. - Non-GAAP net income for Q3 2025 was $24.5 million, or $0.38 per diluted share, compared to $55.0 million, or $0.70 per diluted share, in Q3 2024 [9]. Operational Highlights - Revenues from consumables and services increased by 26% year-over-year, totaling $19.9 million in Q3 2025 [6]. - The company maintained a total cash position of $532.3 million as of September 30, 2025, which includes cash and cash equivalents, marketable securities, and short-term bank deposits [10]. Management Commentary - CEO Moshe Mizrahy noted that the third quarter progressed in line with expectations despite ongoing global uncertainties, emphasizing the company's focus on strategic investments for long-term growth [4][5]. - CFO Yair Malca highlighted that gross margins were in line with expectations, reflecting proactive planning around tariff impacts [6]. Future Outlook - Management expects full-year revenues for 2025 to remain between $365 million and $375 million, with non-GAAP gross margins projected between 78% and 80% [15].

Core Insights - InMode Ltd. has appointed Michael Dennison as President of North America, highlighting his extensive experience in the aesthetic medical device industry and his previous leadership roles within the company [1][2]. Company Overview - InMode is a leading global provider of innovative medical technologies, specializing in devices that utilize novel radiofrequency (RF) technology for various medical applications, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [3]. Leadership and Strategy - Michael Dennison's promotion is seen as a strategic move to enhance InMode's market presence and drive growth in North America, with a focus on cultivating talent and achieving market excellence [2]. - Dennison aims to build on InMode's strong foundation and accelerate momentum in the North American market, delivering greater value to partners and setting new industry standards [2]. Financial Performance - InMode expects to report third-quarter 2025 revenue between $92.5 million and $93.0 million, reiterating its full-year 2025 guidance of $365 million to $375 million [5].

Core Insights - InMode Ltd. (NASDAQ: INMD) stock is trading near its 52-week lows, having experienced upper single-digit losses this year, indicating a potential investment opportunity ahead of its Q3 update [1] Company Overview - InMode Ltd. is currently facing a decline in stock price, which may present an appealing investment opportunity for investors [1] Analyst Background - The analysis is provided by a seasoned financial professional with extensive experience in financial analysis and investment research, emphasizing a strong background in capital markets and macro-economy [1] Investment Focus - The analyst is focused on building an international investment portfolio and aims to share insights and strategies with the global investing community [1]

Summary of InMode Conference Call Company Overview - **Company**: InMode - **Industry**: Medical Technology, specifically in energy-based, minimally invasive surgical aesthetic and medical treatment solutions Key Points and Arguments Market Conditions - The aesthetic market has been experiencing a slowdown since summer 2023, attributed to macroeconomic factors and softening demand [4][6] - InMode has a strong financial position, being debt-free with a solid cash balance, which allows it to navigate the current market challenges [9] Financing and Credit - Approximately 90% of InMode's capital equipment sales are financed through third-party leasing companies [6] - Rising interest rates have increased monthly payments for customers, leading to tighter credit conditions and more rigorous approval processes [6][7] Product Strategy - InMode has opted not to lower prices, believing it would be detrimental in the long run [16] - The company is expanding its product offerings to include lasers and other technologies, aiming to become a one-stop shop for customers [16][17] Market Penetration - InMode has achieved about 25-30% penetration in the plastic surgeon community but only 5-7% in dermatology, indicating significant growth potential in the latter [20][22] - The company is focusing on upgrading existing customers to newer technologies, which could enhance penetration further [22][32] Patient Demand - There has been a decline in patient demand over the last couple of years, impacting capital equipment sales [58] - Recent months have shown signs of stabilization in demand, although it remains below previous levels [61][63] International Growth - InMode has seen a return to double-digit growth in international markets, attributed to leadership changes and direct operations in countries like Germany and Japan [81][82] - The company is working with a distributor in China and is awaiting approvals for more products, which could enhance sales in that market [87][90] Tariff Impact - The company anticipates a 200-300 basis point headwind from tariffs, with ongoing supply chain adjustments aimed at mitigating this impact [64][70] - Future guidance on tariffs will depend on the success of these adjustments and potential treaties between Israel and the U.S. [69] Future Outlook - InMode is cautiously optimistic about achieving 5-6% revenue growth in the coming years, which would add $25-30 million to the top line annually [94][96] - The company expects new product launches to contribute positively to revenue growth [94] Additional Important Information - The aesthetic space is cyclical, and down cycles typically do not last more than two to three years [12] - The company is actively pursuing opportunities in women's health, which is seen as a significant growth driver [54][56] - InMode is also developing a standalone team focused on ophthalmology, which is expected to boost growth once FDA approvals are secured [53][54]